AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02864160 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison Group
Description: Written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
Study NCT03818451 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Co-ultraPEALut (Glialia)
Description: Co-ultraPEALut is administered to moderate traumatic brain injured patients for 180 days
Study NCT04374045 — intervention group
Intervention type: OTHER
Intervention: ECG-Holter
Description: Patient will have a ECG-Holter recording during all their hospitalization.
Study NCT00745043 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bronchodilator response
Study NCT00745043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bronchodilator response
Study NCT01079494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmaceutical care services
Description: Patients treatment related problems and therapeutic needs or complains identified by clinical pharmacist and managed collaboratively by both pharmacist and the physician.
Study NCT04474015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial electric stimulation
Description: NeuroConn® DC Plus stimulator: the NeuroConn® stimulator can be programmed with specific frequencies of stimulation ranging from 0.5 to 500 Hz. This device is therefore appropriate for the present study to stimulate only at 0.75 or 3.0 Hz. Also, the NeuroConn only allows low current intensities to be chosen. The maximum current intensity that can be delivered with this stimulator is 5 milliamps.
Study NCT04674657 — intervention group
Intervention type: DRUG
Intervention: blood drug concentration
Description: blood drug concentration
Study NCT01771250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin Peglispro
Description: Daily doses administered SC.
Study NCT01771250 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Daily doses administered SC.
Study NCT02058563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix®
Description: 1 dose administered as a subcutaneous (SC) injection.
Study NCT02058563 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine
Description: 1 dose administered subcutaneously.
Study NCT04280731 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fermented quinoa
Description: Quinoa drink fermented with lactic acid bacteria isolated from food
Study NCT04673760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialized palliative home care
Description: Specialist palliative home care teams will initiate care as usual, including managing a systematic and collaborative process of advance care planning with patients, family caregivers, GPs and SPITEX nurses using the Betreuungsplan, information packages and regular case meetings. The GP was additionally provided with educational palliative care information by the study team.
Study NCT00606463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Ablation (Gen2 Cardiac Ablation System)
Description: Ablation of isthmus-dependent atrial flutter
Study NCT02534246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound biopsy needle Echo Tip ProCore
Description: Two passes preformed with Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) and two passes will be performed using SharkCore ultrasound biopsy needle (Medtronic \[Beacon\] 25 gauge) from single lesion.
Study NCT02534246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound biopsy needle SharkCore
Study NCT01921764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace physical exercise
Study NCT01921764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home physical exercise
Study NCT02415270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Nicotine Cigarettes
Description: Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
Study NCT02415270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced ROS/RNS
Description: Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
Study NCT02415270 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Human topography data will show if smokers change the way they smoke due to being in a research study. Select biosamples of participants will be used to analyze how biomarkers differ among groups
Study NCT01647776 — intervention group
Intervention type: OTHER
Intervention: Stool DNA Test
Description: Stool DNA test is done prior to the colonoscopy.
Study NCT01647776 — intervention group
Intervention type: PROCEDURE
Intervention: biopsies of rectal and colon mucosa
Description: During the standard of care colonoscopy biopsies of rectal and colon mucosa will be taken for analysis of 15-PGDH pathway factors \[levels of prostaglandin E2 (PG E2), and mRNA for 15-PGDH, COX-1 and COX-2 expression\] as markers of risk of developing adenoma.
Study NCT01647776 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: A Food Frequency Questionnaire (FFQ), a Meat Preparation Questionnaire (MPQ), and a Physical Activity Questionnaire (PAQ), all developed at the University of Arizona Cancer Center will be used to collect dietary and physical activity data. Risk Factor Questionnaire (RFQ) developed by the University of Southern California will be used to collect general risk information. Stool (sDNA) test patient satisfaction survey.
Study NCT03965416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Coat
Description: We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
Study NCT03965416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Without White Coat
Description: We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
Study NCT00461084 — intervention group
Intervention type: DRUG
Intervention: BIAXIN (CLARITHROMYCIN)
Description: Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
Study NCT00461084 — intervention group
Intervention type: DRUG
Intervention: Biaxin (clarithromycin)
Description: Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
Study NCT02982057 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: the ABSORB:bioresorbable vascular scaffold
Study NCT02982057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: O.M.T
Study NCT02788708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02213094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide 500 mg
Description: Nicotinamide 500 mg taken by mouth each morning
Study NCT04039217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy
Description: Participants will be given two doses of the oral fixed dose combination anti-HIV medication Biktarvy (BIC/FTC/TAF) separated by 24 hours. The first dose is given in the clinic and participants are instructed to take the second dose at home, 24 hours after the first dose.
Study NCT03364309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study NCT03364309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC
Study NCT03364309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT02213094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide 1000 mg
Description: Nicotinamide 1000 mg taken by mouth each morning
Study NCT00711009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir (LPV/r)
Description: LPV/r 400/100 mg BID
Study NCT00711009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r)
Description: LPV/r 400/100 mg BID
Study NCT01371552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: delefilcon A contact lens
Description: Investigational, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1 and one week in Part 2.
Study NCT00711009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Description: FTC/TDF 200/300 mg QD
Study NCT01371552 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: delefilcon A contact lens
Description: Investigational, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1 and one week in Part 2.
Study NCT01371552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: filcon II 3 contact lenses
Description: Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
Study NCT01371552 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: filcon II 3 contact lenses
Description: Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
Study NCT01371552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon A contact lenses
Description: Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
Study NCT01371552 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narafilcon A contact lenses
Description: Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
Study NCT00711009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir (RAL)
Description: RAL 400 mg BID
Study NCT01270139 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation of nanoparticles
Description: 60 patients into nanogroup with the use of 60/15-70/40 nm silica-gold nanoparticles (NPs) transplanted by endoscopic cardiac surgery in the composition of bioengineered on-artery patch grown on the basis of biopolymeric scaffold and host circulating CD45-CD34-CD73+CD105+ progenitor cells
Study NCT01270139 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transplantation of iron-bearing nanoparticles
Description: 60 - into ferro-magnetic group with 60/15-70/40 nm silica-gold iron-bearing NPs with delivery in hand of magnetic navigation system
Study NCT00032357 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ferritin reduction to 25 ng/ml by phlebotomy
Study NCT03477838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle LibrePro CGM
Description: a professional CGM device will be worn by the participant for up to 14 days
Study NCT02519595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine IV 1mg/kg
Description: Intervention: Ketamine IV 1mg/kg
Study NCT02519595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine IV 1.5mg/kg
Description: Intervention: Ketamine IV 1.5 mg/kg
Study NCT02519595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine IV 2mg/kg
Description: Intervention: Ketamine IV 2 mg/kg
Study NCT01477489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Starting dose of veliparib will be 50 mg taken twice daily and will escalate up to a possible 200 mg twice daily.
Study NCT01477489 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard radiation treatment
Description: Limited to 60 Gy.
Study NCT02720406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous ketamine0.5mg/kg
Description: Intravenous ketamine 0.5mg/kg after anesthesia and before surgery.
Study NCT02720406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Ketamine 1mg/kg
Description: Nebulized Ketamine 1mg/kg given by nebulizer before anesthesia.
Study NCT02720406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Ketamine 2mg/kg
Description: Nebulized Ketamine 2mg/kg given by nebulizer before anesthesia.
Study NCT02720406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: Saline 0.9% given by nebulizer before anesthesia and iv after anesthesia and before surgery.
Study NCT01903629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MCE
Description: MCE first, followed by standard gastroscopy
Study NCT01903629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard gastroscopy
Study NCT01810718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Maximum tolerated dosage (MTD) will be defined in Phase I. First 3 patients (pts) will receive Nilotinib 200mg daily dose. If no dose limiting toxicities after at least 1month the next 3 pts will be treated with 300mg. If are>=2 dose limiting toxicities the Phase I will end and MTD will be defined as the next lower dosage. If they will observe 1dose limiting toxicities, they will treat other 3 pts (same dosage); if there isn't dose limiting toxicity, they will increase the dosage in the next cohort; but if they will observe another dose limiting toxicity (tot limiting toxicities 2/6 pts), the study will continue using the previous dose. MTD will be considered the maximum dosage used to treat 6 pts achieving at most 1 dose limiting toxicities, or the previous dosage if with this dosage they we will achieve 2 dose limiting toxicities. Doses will not be escalated beyond >600 or \<200mg/die The MTD will be used for phase II
Study NCT01270139 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stenting
Description: 60 - in sirolimus-eluting stenting control
Study NCT04374331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video-assisted training
Description: The patients in the VAT group watch a training video in the patient rooms before RCR. The VAT prepared by the researchers consisted of information about things to pay attention to in the hospital in the early period after RCR (nursing care on post-operative day 1, early mobilization, pain control, shoulder protection, and wearing/removing the shoulder sling), maintaining ADL at home (bathing, nutrition, eating, sleeping position, driving, doing household chores, sexual life, worship, and safety measures to be taken at home) and gradual exercise programs (for the first 90 days after discharge).
Study NCT00265382 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ziprasidone oral capsules
Description: Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid.
Study NCT02460185 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Study group: Maternal Physical Exercise
Description: Exercise: 30 minutes of walking, 3 times a week at 4 Km/h.
Study NCT02395445 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orotracheal intubation
Study NCT03372304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Description: Perineural infusion of Ropivacaine 0.2% using a peripheral nerve block catheter and a portable infusion pump.
Study NCT03372304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2%
Description: Perineural infusion of Ropivacaine 0.2% using a peripheral nerve block catheter and a portable infusion pump.
Study NCT03848936 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey includes age, gender, cerebral palsy type, education, mental status, working status, living conditions, comorbidities, pain, spasticity, contractures, deformities, mobility status and gross motor function classification system level
Study NCT02397057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectafer
Study NCT02397057 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04403815 — intervention group
Intervention type: PROCEDURE
Intervention: vascular access for coronary procedures
Description: comparison of x-rays exposition of interventional cardiologist according to vascular access used
Study NCT03639493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exforge® tab 10/160mg, Crestor® tab 20mg
Description: Co-administration of Amlodipine 10mg/ Valsartan 160mg(combination drug) and Rosuvastatin 20mg
Study NCT02518633 — intervention group
Intervention type: DEVICE
Intervention: Continuous positive airway pressure devices
Description: overnight use of CPAP device
Study NCT03120715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estrogen
Description: The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is \<7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.
Study NCT03120715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: estrogen
Description: The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is \<7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.
Study NCT03120715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin
Description: If the endometrial thickness is greater than 9 mm, hCG 10000 IU will be administered via intramuscular injection.And low molecular weight heparin (LMWH) will be injected subcutaneously 4100 IU (WHO) every other day before FET.Then on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
Study NCT03120715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hCG
Description: If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.
Study NCT03120715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hCG
Description: If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.
Study NCT03120715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progesterone
Description: on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
Study NCT03120715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: progesterone
Description: on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
Study NCT02741427 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional toothpaste
Description: The participants should brush their teeth with conventional toothpaste for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on their toothbrushes, use dental floss, but not mouth rinse.
Study NCT02741427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whitening toothpaste
Description: The subjects should brush teeth with whitening toothpaste containing blue pigment for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on toothbrushes, use dental floss, but not mouth rinse.
Study NCT02741427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10% carbamide peroxide
Description: The subjects should dispense the bleaching gel at night into the trays (maxillary and mandibular) and to insert them to cover at least the anterior teeth for a period of 4 h per day, over a 2-week period. Both arches should be bleached at the same time. During the period of bleaching, volunteers should receive the same toothpaste used by G1, in other words, without whitening agents, to standardize their oral hygiene regimen
Study NCT03639493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30060 10/160/20mg
Description: Fixed-dose combination drug containing Amlodipine 10mg and Valsartan 160mg and Rosuvastatin 20mg
Study NCT00523081 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Half the teens in the study will also meet with a research counselor for five to nine individual, weekly sessions that last about 50 minutes each. Whether a teen attends the weekly counseling sessions is decided by chance, like flipping a coin. If teens are assigned to these sessions, they will learn ways to deal with stress and feel better. If teens take part in the counseling sessions, the study counselor will also talk to the teen's doctor from time to time to help plan for the best possible care.